Literature DB >> 29121788

Fluorescence image-guided neurosurgery.

Sadao Kaneko1, Muftah S Eljamel2.   

Abstract

Surgery plays an important role in the management of high-grade gliomas (HGG) and imparts significant tumor-free and overall survival advantages. However HGG margins are often invisible, making their gross total resection (GTR) a difficult task. Hence intraoperative technology such as intraoperative fluorescence was a revolutionary discovery. A critical literature review revealed fluorescence improved the GTR of HGG from 36% using standard surgery to 74.5 and 84.4% using aminolevulinic acid (ALA) or fluorescein (FLCN), respectively. The differences between ALA-fluorescence image-guided neurosurgery (FIGS) and FLCN-FIGS in HGG were not statistically significant. However, the cost per quality added life years was US$16,218 and US$3181 for ALA-FIGS and FLCN-FIGS, respectively. Therefore, FIGS provided a reliable intraoperative tumor marker. Both ALA- and FLCN-FIGS significantly improved GTR and were cost-effective.

Entities:  

Keywords:  ALA; fluorescein; fluorescence; glioma; image guidance; meningioma; surgical resection

Mesh:

Year:  2017        PMID: 29121788     DOI: 10.2217/fon-2017-0194

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

Review 1.  State-of-the-art imaging for glioma surgery.

Authors:  Niels Verburg; Philip C de Witt Hamer
Journal:  Neurosurg Rev       Date:  2020-06-30       Impact factor: 3.042

Review 2.  Effect of 5-Aminolevulinic Acid and Sodium Fluorescein on the Extent of Resection in High-Grade Gliomas and Brain Metastasis.

Authors:  Lasse Cramer Ahrens; Mathias Green Krabbenhøft; Rasmus Würgler Hansen; Nikola Mikic; Christian Bonde Pedersen; Frantz Rom Poulsen; Anders Rosendal Korshoej
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

Review 3.  Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology.

Authors:  Jun Yang; Zhuyan Shi; Ruiyuan Liu; Yanyue Wu; Xin Zhang
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.